Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Identifieur interne : 001122 ( PubMed/Checkpoint ); précédent : 001121; suivant : 001123Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Auteurs : A. Bamias [Grèce] ; E. Gibbs [Australie] ; C. Khoon Lee [Australie] ; L. Davies [Australie] ; M. Dimopoulos [Grèce] ; F. Zagouri [Grèce] ; A-S Veillard [Australie] ; J. Kosse [Allemagne] ; A. Santaballa [Espagne] ; M R Mirza [Danemark] ; G. Tabaro [Italie] ; I. Vergote [Belgique] ; H. Bloemendal [Pays-Bas] ; M. Lykka [Grèce] ; A. Floquet ; V. Gebski [Australie] ; E. Pujade-Lauraine [France]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomized to chemotherapy alone.
DOI: 10.1093/annonc/mdx228
PubMed: 28481967
Affiliations:
- Allemagne, Australie, Belgique, Danemark, Espagne, France, Grèce, Italie, Pays-Bas
- Attique (région), Hovedstaden, Nouvelle-Galles du Sud, Île-de-France
- Athènes, Copenhague, Paris, Sydney
- Université de Sydney
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28481967Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.</title><author><name sortKey="Bamias, A" sort="Bamias, A" uniqKey="Bamias A" first="A" last="Bamias">A. Bamias</name><affiliation wicri:level="3"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Gibbs, E" sort="Gibbs, E" uniqKey="Gibbs E" first="E" last="Gibbs">E. Gibbs</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Khoon Lee, C" sort="Khoon Lee, C" uniqKey="Khoon Lee C" first="C" last="Khoon Lee">C. Khoon Lee</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Dimopoulos, M" sort="Dimopoulos, M" uniqKey="Dimopoulos M" first="M" last="Dimopoulos">M. Dimopoulos</name><affiliation wicri:level="3"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Zagouri, F" sort="Zagouri, F" uniqKey="Zagouri F" first="F" last="Zagouri">F. Zagouri</name><affiliation wicri:level="3"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Veillard, A S" sort="Veillard, A S" uniqKey="Veillard A" first="A-S" last="Veillard">A-S Veillard</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Kosse, J" sort="Kosse, J" uniqKey="Kosse J" first="J" last="Kosse">J. Kosse</name><affiliation wicri:level="1"><nlm:affiliation>AGO and Department of Gynaecology, Sana Klinikum Offenbach, Offenbach, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>AGO and Department of Gynaecology, Sana Klinikum Offenbach, Offenbach</wicri:regionArea><wicri:noRegion>Offenbach</wicri:noRegion><wicri:noRegion>Offenbach</wicri:noRegion><wicri:noRegion>Offenbach</wicri:noRegion></affiliation></author><author><name sortKey="Santaballa, A" sort="Santaballa, A" uniqKey="Santaballa A" first="A" last="Santaballa">A. Santaballa</name><affiliation wicri:level="1"><nlm:affiliation>GEICO and Medical Oncology Department, University Hospital and Polytechnic, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>GEICO and Medical Oncology Department, University Hospital and Polytechnic, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Mirza, M R" sort="Mirza, M R" uniqKey="Mirza M" first="M R" last="Mirza">M R Mirza</name><affiliation wicri:level="3"><nlm:affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Tabaro, G" sort="Tabaro, G" uniqKey="Tabaro G" first="G" last="Tabaro">G. Tabaro</name><affiliation wicri:level="1"><nlm:affiliation>MITO and USCC/Dir. Scientifica, Centro di Riferimento Oncologico, CRO-IRCCS, Aviano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>MITO and USCC/Dir. Scientifica, Centro di Riferimento Oncologico, CRO-IRCCS, Aviano</wicri:regionArea><wicri:noRegion>Aviano</wicri:noRegion></affiliation></author><author><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I" last="Vergote">I. Vergote</name><affiliation wicri:level="1"><nlm:affiliation>BGOG and Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>BGOG and Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Bloemendal, H" sort="Bloemendal, H" uniqKey="Bloemendal H" first="H" last="Bloemendal">H. Bloemendal</name><affiliation wicri:level="1"><nlm:affiliation>DGOG and Department of Internal Medicine/Oncology, Meander Medical Center, Amersfoort, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>DGOG and Department of Internal Medicine/Oncology, Meander Medical Center, Amersfoort</wicri:regionArea><wicri:noRegion>Amersfoort</wicri:noRegion></affiliation></author><author><name sortKey="Lykka, M" sort="Lykka, M" uniqKey="Lykka M" first="M" last="Lykka">M. Lykka</name><affiliation wicri:level="3"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Floquet, A" sort="Floquet, A" uniqKey="Floquet A" first="A" last="Floquet">A. Floquet</name><affiliation><nlm:affiliation>GINECO and Medical Oncology and Genetics Department, Institut Bergonié, Bordeaux.</nlm:affiliation><wicri:noCountry code="subField">Bordeaux</wicri:noCountry></affiliation></author><author><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><affiliation wicri:level="3"><nlm:affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28481967</idno><idno type="pmid">28481967</idno><idno type="doi">10.1093/annonc/mdx228</idno><idno type="wicri:Area/PubMed/Corpus">000744</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000744</idno><idno type="wicri:Area/PubMed/Curation">000741</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000741</idno><idno type="wicri:Area/PubMed/Checkpoint">000741</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000741</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.</title><author><name sortKey="Bamias, A" sort="Bamias, A" uniqKey="Bamias A" first="A" last="Bamias">A. Bamias</name><affiliation wicri:level="3"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Gibbs, E" sort="Gibbs, E" uniqKey="Gibbs E" first="E" last="Gibbs">E. Gibbs</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Khoon Lee, C" sort="Khoon Lee, C" uniqKey="Khoon Lee C" first="C" last="Khoon Lee">C. Khoon Lee</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Dimopoulos, M" sort="Dimopoulos, M" uniqKey="Dimopoulos M" first="M" last="Dimopoulos">M. Dimopoulos</name><affiliation wicri:level="3"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Zagouri, F" sort="Zagouri, F" uniqKey="Zagouri F" first="F" last="Zagouri">F. Zagouri</name><affiliation wicri:level="3"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Veillard, A S" sort="Veillard, A S" uniqKey="Veillard A" first="A-S" last="Veillard">A-S Veillard</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Kosse, J" sort="Kosse, J" uniqKey="Kosse J" first="J" last="Kosse">J. Kosse</name><affiliation wicri:level="1"><nlm:affiliation>AGO and Department of Gynaecology, Sana Klinikum Offenbach, Offenbach, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>AGO and Department of Gynaecology, Sana Klinikum Offenbach, Offenbach</wicri:regionArea><wicri:noRegion>Offenbach</wicri:noRegion><wicri:noRegion>Offenbach</wicri:noRegion><wicri:noRegion>Offenbach</wicri:noRegion></affiliation></author><author><name sortKey="Santaballa, A" sort="Santaballa, A" uniqKey="Santaballa A" first="A" last="Santaballa">A. Santaballa</name><affiliation wicri:level="1"><nlm:affiliation>GEICO and Medical Oncology Department, University Hospital and Polytechnic, Valencia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>GEICO and Medical Oncology Department, University Hospital and Polytechnic, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Mirza, M R" sort="Mirza, M R" uniqKey="Mirza M" first="M R" last="Mirza">M R Mirza</name><affiliation wicri:level="3"><nlm:affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Tabaro, G" sort="Tabaro, G" uniqKey="Tabaro G" first="G" last="Tabaro">G. Tabaro</name><affiliation wicri:level="1"><nlm:affiliation>MITO and USCC/Dir. Scientifica, Centro di Riferimento Oncologico, CRO-IRCCS, Aviano, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>MITO and USCC/Dir. Scientifica, Centro di Riferimento Oncologico, CRO-IRCCS, Aviano</wicri:regionArea><wicri:noRegion>Aviano</wicri:noRegion></affiliation></author><author><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I" last="Vergote">I. Vergote</name><affiliation wicri:level="1"><nlm:affiliation>BGOG and Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>BGOG and Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Bloemendal, H" sort="Bloemendal, H" uniqKey="Bloemendal H" first="H" last="Bloemendal">H. Bloemendal</name><affiliation wicri:level="1"><nlm:affiliation>DGOG and Department of Internal Medicine/Oncology, Meander Medical Center, Amersfoort, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>DGOG and Department of Internal Medicine/Oncology, Meander Medical Center, Amersfoort</wicri:regionArea><wicri:noRegion>Amersfoort</wicri:noRegion></affiliation></author><author><name sortKey="Lykka, M" sort="Lykka, M" uniqKey="Lykka M" first="M" last="Lykka">M. Lykka</name><affiliation wicri:level="3"><nlm:affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens</wicri:regionArea><placeName><settlement type="city">Athènes</settlement><region nuts="2" type="region">Attique (région)</region></placeName></affiliation></author><author><name sortKey="Floquet, A" sort="Floquet, A" uniqKey="Floquet A" first="A" last="Floquet">A. Floquet</name><affiliation><nlm:affiliation>GINECO and Medical Oncology and Genetics Department, Institut Bergonié, Bordeaux.</nlm:affiliation><wicri:noCountry code="subField">Bordeaux</wicri:noCountry></affiliation></author><author><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name><affiliation wicri:level="4"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea><orgName type="university">Université de Sydney</orgName><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation></author><author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><affiliation wicri:level="3"><nlm:affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomized to chemotherapy alone.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28481967</PMID><DateCreated><Year>2017</Year><Month>05</Month><Day>08</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>8</Issue><PubDate><Year>2017</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.</ArticleTitle><Pagination><MedlinePgn>1842-1848</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdx228</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">In the open-label randomized phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomized to chemotherapy alone.</AbstractText><AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">In AURELIA, 361 women with PROC were randomized to chemotherapy alone or with bevacizumab. Patients initially randomized to chemotherapy were offered bevacizumab after PD. Post hoc analyses assessed efficacy and safety in three subgroups: chemotherapy alone, chemotherapy followed by bevacizumab after PD, and chemotherapy plus bevacizumab at randomization.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Of the 182 patients randomized to chemotherapy alone, 72 (40%) received bevacizumab after PD and 110 (60%) never received bevacizumab. There were no significant differences in patient and disease characteristics between these subgroups at baseline or the time of PD. Compared with patients never receiving bevacizumab, the risk of death was significantly reduced in patients receiving bevacizumab either upfront with chemotherapy [hazard ratio (HR) = 0.68, 95% confidence interval (CI) 0.52-0.90] or after PD (HR = 0.60, 95% CI 0.43-0.86). The tolerability of bevacizumab was similar with administration upfront or after PD.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Post-PD bevacizumab use may have confounded OS results in AURELIA. In these exploratory analyses of non-randomized subgroups, bevacizumab use, either with chemotherapy or after PD on chemotherapy alone, improved OS compared with no bevacizumab. Combining bevacizumab with chemotherapy at first appearance of platinum resistance maximises the likelihood of patients receiving this active treatment for PROC. ClinicalTrials.gov: NCT00976911.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bamias</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbs</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoon Lee</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimopoulos</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagouri</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veillard</LastName><ForeName>A-S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosse</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AGO and Department of Gynaecology, Sana Klinikum Offenbach, Offenbach, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santaballa</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GEICO and Medical Oncology Department, University Hospital and Polytechnic, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirza</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tabaro</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>MITO and USCC/Dir. Scientifica, Centro di Riferimento Oncologico, CRO-IRCCS, Aviano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vergote</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>BGOG and Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloemendal</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>DGOG and Department of Internal Medicine/Oncology, Meander Medical Center, Amersfoort, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lykka</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HECOG and Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Floquet</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GINECO and Medical Oncology and Genetics Department, Institut Bergonié, Bordeaux.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebski</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>GINECO and Paris Descartes University, AP-HP Central Paris University Hospitals, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bevacizumab</Keyword><Keyword MajorTopicYN="N">combination therapy</Keyword><Keyword MajorTopicYN="N">overall survival</Keyword><Keyword MajorTopicYN="N">platinum-resistant ovarian cancer</Keyword><Keyword MajorTopicYN="N">sequence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28481967</ArticleId><ArticleId IdType="pii">3804470</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdx228</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Danemark</li><li>Espagne</li><li>France</li><li>Grèce</li><li>Italie</li><li>Pays-Bas</li></country><region><li>Attique (région)</li><li>Hovedstaden</li><li>Nouvelle-Galles du Sud</li><li>Île-de-France</li></region><settlement><li>Athènes</li><li>Copenhague</li><li>Paris</li><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><noCountry><name sortKey="Floquet, A" sort="Floquet, A" uniqKey="Floquet A" first="A" last="Floquet">A. Floquet</name></noCountry><country name="Grèce"><region name="Attique (région)"><name sortKey="Bamias, A" sort="Bamias, A" uniqKey="Bamias A" first="A" last="Bamias">A. Bamias</name></region><name sortKey="Dimopoulos, M" sort="Dimopoulos, M" uniqKey="Dimopoulos M" first="M" last="Dimopoulos">M. Dimopoulos</name><name sortKey="Lykka, M" sort="Lykka, M" uniqKey="Lykka M" first="M" last="Lykka">M. Lykka</name><name sortKey="Zagouri, F" sort="Zagouri, F" uniqKey="Zagouri F" first="F" last="Zagouri">F. Zagouri</name></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Gibbs, E" sort="Gibbs, E" uniqKey="Gibbs E" first="E" last="Gibbs">E. Gibbs</name></region><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name><name sortKey="Khoon Lee, C" sort="Khoon Lee, C" uniqKey="Khoon Lee C" first="C" last="Khoon Lee">C. Khoon Lee</name><name sortKey="Veillard, A S" sort="Veillard, A S" uniqKey="Veillard A" first="A-S" last="Veillard">A-S Veillard</name></country><country name="Allemagne"><noRegion><name sortKey="Kosse, J" sort="Kosse, J" uniqKey="Kosse J" first="J" last="Kosse">J. Kosse</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Santaballa, A" sort="Santaballa, A" uniqKey="Santaballa A" first="A" last="Santaballa">A. Santaballa</name></noRegion></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Mirza, M R" sort="Mirza, M R" uniqKey="Mirza M" first="M R" last="Mirza">M R Mirza</name></region></country><country name="Italie"><noRegion><name sortKey="Tabaro, G" sort="Tabaro, G" uniqKey="Tabaro G" first="G" last="Tabaro">G. Tabaro</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I" last="Vergote">I. Vergote</name></noRegion></country><country name="Pays-Bas"><noRegion><name sortKey="Bloemendal, H" sort="Bloemendal, H" uniqKey="Bloemendal H" first="H" last="Bloemendal">H. Bloemendal</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001122 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001122 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28481967
|texte= Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28481967" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |